{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:37:14Z","timestamp":1782549434476,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clgc.2024.102248","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T03:39:28Z","timestamp":1730259568000},"page":"102248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial"],"prefix":"10.1016","volume":"23","author":[{"given":"Ronac","family":"Mamtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9203-4245","authenticated-orcid":false,"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-1250","authenticated-orcid":false,"given":"Alvaro Montesa","family":"Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0376-5642","authenticated-orcid":false,"given":"Urbano Anido","family":"Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-6139","authenticated-orcid":false,"given":"Mehmet A\uff0e N.","family":"\u015eendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-1554","authenticated-orcid":false,"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9764-0845","authenticated-orcid":false,"given":"Olivier","family":"Huillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8378-3001","authenticated-orcid":false,"given":"Hyo Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rustem","family":"Gafanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avishay","family":"Sella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hwa","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1246-5601","authenticated-orcid":false,"given":"Kentaro","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca Homet","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-1605","authenticated-orcid":false,"given":"Jin Zhi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajjai","family":"Alva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102248_bib0001","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.102248_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102187","article-title":"Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: applying clinical trial findings to clinical practice","volume":"97","author":"Grivas","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2024.102248_bib0003","unstructured":"BAVENCIO\u00ae (avelumab) 20 mg\/mL concentrate for solution for infusion (summary of product characteristics). 10\/2024. Modugno, Italy: Merck Serono S.p.A.; 2024."},{"key":"10.1016\/j.clgc.2024.102248_bib0004","unstructured":"BAVENCIO\u00ae (avelumab) injection, for intravenous use (prescribing information) 03\/2024. Rockland, MA: EMD Serono Inc.; 2024."},{"key":"10.1016\/j.clgc.2024.102248_bib0005","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102248_bib0006","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102248_bib0007","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102248_bib0008","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102248_bib0009","unstructured":"US Food and Drug Administration. FDA approves avelumab for urothelial carcinoma maintenance treatment. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment. Accessed November 13, 2024."},{"key":"10.1016\/j.clgc.2024.102248_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.8395","article-title":"Uptake of maintenance immunotherapy and changes in upstream treatment selection among patients with urothelial cancer","volume":"6","author":"Mamtani","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"suppl 6","key":"10.1016\/j.clgc.2024.102248_bib0011","article-title":"US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102248_bib0012","first-page":"319","article-title":"Andres-Pons A. Treatment of patients with advanced urothelial carcinoma in routine care in Germany: initial data from the CARAT-UBC cohort","volume":"45","author":"Goebell","year":"2022","journal-title":"Oncol Res Treat"},{"issue":"suppl 4","key":"10.1016\/j.clgc.2024.102248_bib0013","article-title":"Updated results from AVENANCE: real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment","volume":"42","author":"Barthelemy","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.clgc.2024.102248_bib0014","article-title":"Avelumab first-line maintenance therapy for locally advanced\/metastatic urothelial carcinoma: results from the real-world US PATRIOT-II study","volume":"42","author":"Grivas","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102248_bib0015","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/iju.15473","article-title":"AVENUE: a retrospective, real-world study evaluating patientcharacteristics and outcomes in patients with advanced urothelial carcinomatreated with avelumab first-line maintenance therapy in Japan","volume":"31","author":"Kikuchi","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2024.102248_bib0016","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jjco\/hyac186","article-title":"Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study","volume":"53","author":"Miyake","year":"2023","journal-title":"Jpn J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.clgc.2024.102248_bib0017","article-title":"Avelumab first-line maintenance (1LM) in patients (pts) with locally advanced or metastatic urothelial carcinoma (la\/mUC) in the Czech Republic: interim real-world results from a national reimbursement registry","volume":"42","author":"Zemankova","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102248_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1403120","article-title":"Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program","volume":"14","author":"Park","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2024.102248_bib0019","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.clgc.2023.06.008","article-title":"Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC): \"real world\" experience","volume":"21","author":"Bakaloudi","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2024.102248_bib0020","article-title":"READY: REAl-world data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma","volume":"5","author":"Antonuzzo","year":"2024","journal-title":"ESMO Real World Data Digital Oncol"},{"key":"10.1016\/j.clgc.2024.102248_bib0021","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clgc.2023.03.011","article-title":"Evaluating real-world characteristics of patients with advanced urothelial carcinoma eligible for avelumab maintenance therapy: a multicountry retrospective medical chart review","volume":"21","author":"Bellmunt","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2024.102248_bib0022","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102248_bib0023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.20517\/2394-4722.2022.04","article-title":"Determinants of prognosis in metastatic urothelial carcinoma: a review of the literature","volume":"8","author":"Hui","year":"2022","journal-title":"J Cancer Metastasis Treat"},{"issue":"suppl 6","key":"10.1016\/j.clgc.2024.102248_bib0024","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy","volume":"41","author":"Sridhar","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:30:38Z","timestamp":1762551038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324002180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1558767324002180"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102248","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. and The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102248"}}